Using a smartwatch and phone app to estimate Parkinson's disease risk
Tests an artificial intelligence model that estimates Parkinson's disease risk in people over 50.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study
Key facts
- Where
- Madrid, SpainSee the site
Where in Spain
- Fundación Iniciativa para las Neurociencias. Hospital Ruber Internacional.Madrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Queen Mary University of London
- Trial code
- NCT07706829
- Record updated
- 2 October 2026
- Original description
The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.Read full original descriptionShow less
Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study
The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.
Inclusion: Age ≥ 50 years; At least one of the following clinical markers for PD risk:; REM sleep behaviour disorder (RBD) confirmed with polysomnography; Neurogenic orthostatic hypotension (nOH) defined as a drop in systolic / diastolic blood pressure ≥ 20/10mmHg within 3 minutes of active standing or tilt-table test, and with a blunted heart rate response (ΔHeart rate/ΔSBP ratio < 0.5 bpm/mmHg); Objective hyposmia defined as University of Pennsylvania Smell Identification Test (UPSIT) score ≤ 15th percentile for age and sex; Able and willing to give informed written consent; Use of compatible smartphone (mobile operating system Android version 11 or newer). A smartwatch will be provided to each participant for the duration of the study.
Exclusion: Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of investigator); Active treatment with neuroleptics, reserpine or metoclopramide (these drugs should be discontinued for at least 6 months before screening visit) due to their interference with dopamine transporter SPECT imaging acquisition and interpretation; Concomitant participation in interventional studies; Clinical diagnosis of Parkinson's disease (PD) according to MDS clinical diagnostic criteria; Dementia defined as deterioration of cognitive function severe enough to impair functioning on daily activities; Pregnant women; Unwilling or unable to give informed written consent; Vulnerable individuals as defined by the HRA; Inability to use the smartwatch and/or the mAI-Health app for the purpose of the study as judged by the investigator.